|  |
| GSK Teams with Shenzhen Neptunus for Chinese Vaccines
| GlaxoSmithKline is expanding its influenza vaccine efforts through a joint R&D alliance with Shenzhen Neptunus. The goal: to tap the world’s biggest market and attempt to deliver flu shots to more than a billion people. | | | GSK Signs Deal with Concert Pharma to the Tune of $1 Billion
| | GlaxoSmithKline has entered into a collaboration deal with Concert to create drugs using deuterium—“heavy hydrogen”—that can be gathered from seawater and used to alter the way molecules perform in the body. | | | GSK Grabs Derma Firm for $2.9 Billion
| | Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line. | | | Pfizer and Glaxo Join Forces in HIV Venture
|
| The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market. | | | A Season in Financial Hell
| | From the depths of the Great Recession, Pharm Exec called in pros on all sides of the M&A business to help us deal. | | | Gilead Buys CV Therapeutics (Update 1)
| | The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion. | | | Roche and Genentech Seal the Deal for $46.8 Billion
| | After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant. | | | Merck Takes Unusual Merger Tactic in Schering Deal
| | The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move? | |
| Astellas to Nominate Two Directors to CV Therapeutics Board
| | Astellas's hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board members and replace them with their own. | |  MORE ARTICLES
|
| |
| |
| |
| India: An Emerging Knowledge Superpower
| | "India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub." For Dilip Shah, General Secretary of the Indian Pharmaceutical Alliance (IPA), India is currently on its way to undertake one of the greatest transformations ever experienced within the pharmaceutical industry, although the excitement has been over 30 years in the making. | | | MORE ARTICLES
|
| |
| Measuring the Value of KOL Interactions
| | Thought leaders are a critical component of a pharmaceutical company?s professional marketing and medical strategies. But companies face a real challenge in creating, maintaining, and leveraging those relationships while safely navigating logistical issues and regulatory waters. | | | UCB Teams with PatientsLikeMe to Learn What Patients Want
| | In an effort to learn as more about epilepsy sufferers, UCB will implement a social network that allows patients to communicate about their disease state and treatments. Think of it as one giant, online clinical trial. | | | Wyeth Winds Up With New Pristiq Campaign
| | What do you do when you are introducing a new drug in an already crowded category? Wyeth queried depression sufferers to find out what they want to see in a drug ad before launching its new DTC campaign for Pristiq. | | | On the Right Pathways
| | With staggering year-over-year growth, biosimilars are "the future of medicine." Marketers must position their companies for the inevitable changes. | | | Learning to Relate
| | A multi-phase implementation strategy can debunk the myth that social media won't work for pharma. | | | Amgen and CDC to Spearhead Anti-infection Campaign
| | Cancer patients worry not only about their disease, but also the side effects of the drugs they take to treat it. Now the Centers for Disease Control and Prevention and biologics firm Amgen are partnering on a multi-prong program to get patients to pay attention to another, related, danger: chemo-related infections. | |
| | New Bill to Curb Pharma ED Ads
| | Two Democratic Congressman have brewed up new legislation to target pharma erectile dysfunction ads rather than going after advertisements with sexually suggestive material in general. Industry experts don't think they have a chance, but the bill could still be a pain for fans of Viva Viagra. | | | Weathering the Storm
| | Marketers must stress that maintaining good health behaviors is one of the best things people can do to survive a down market. | | | Ad(Ventures) in Pharmaland
| | Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration. | | | MORE ARTICLES
|
| |
| |
| Pharma Trials Heading South
| | Diversity of ethnic groups and prevalence of Spanish language make Latin America an attractive destination for clinical trials. | | | No Such Thing as Free Drugs?
| | New medicines program may be a beacon of light for the newly jobless, but some wonder what issues might arise from such a ?good gesture.? | | | Wrangling Over Research Results
| | Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion. | | | A Review of Tafas v. Doll | | Appeals court paves the way for Patent and Trademark Office to adopt restrictive patent rules. | | | New Study Reveals Distribution Trends in Drug Sampling
| | Drug sampling is way up, but who is receiving the free medication? The American Journal of Public Health states that the majority of samples are distributed to the wealthy and insured. PhRMA, however, disagrees. | | | Data Mining Companies Score Legal Win in Maine
| | IMS Health, and a handful of other intelligence gathering companies, will be allowed to collect prescribing information from physicians in Maine. This is a big win for pharma companies that purchase reports from data mining companies to better market to doctors. The last hurdle is Vermont, which still has an outstanding lawsuit against the firms. | | | BioMS Medical Signs $500 Million Agreement with Lilly
| | Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS. | | | Preemption Gets Boost from Bush
| | State and federal governments do battle over who is responsible for faulty or mislabeled drugs and devices, while patients, pharma manufacturers, and Medtronic wait for answers. Is federal preemption the answer? | | | BMS Cuts Bloated Manufacturing Arm to Bolster R&D
| | Bristol-Myers Squibb halves its manufacturing division and looks to unmet needs for innovation. Expect new oncology, diabetes, and cardiovascular drugs as well as a more streamlined approach to manufacturing. | | | MORE ARTICLES
|
| |
| GSK Chooses MediaCom for a Billion-Dollar Planner Contract
| | GlaxoSmithKline locks up MediaCom as its only ad-buying/planning provider. The agency will handle GSK's massive ad spend, which last year hovered around $1.1 billion. | | | Vertex Pharmaceuticals Brings Transparency Online
| | Drug manufacturer shakes things up with new Web site that functions as an open book into the world of Vertex Pharmaceuticals. The company hopes that its transparent approach to design will be a lesson to pharma companies still fearful of online media. | | | Arkansas Attorney General Takes J&J to Task
| | The State of Arkansas filed suit against Risperdal manufacturer Johnson & Johnson, claiming promotion of the drug for nonmedical uses has led to increased prescriptions being written and bigger payouts by Medicaid. | | | In Defense of Peer Review: Waxman Opponents Argue for Distribution of Off-Label Info
| | Peer-review advocates speak out against Congressman Waxman?s stance on a new policy that would allow pharma to distribute unbiased journal articles to doctors without prior approval. | | | Doc-Driven Search Site Lists Top Search Terms
| | A physician-oriented search engine reveals its most-searched terms. Among the winners: breast and lung cancer, cortisol, and HbA1c/glycated hemoglobin. Nowhere to be seen: pharmaceutical products. | | | Discovery Health Documentary Spotlights Diabetes and Offers a CME Credit
| | A new pharma-sponsored documentary chronicles one doctor?s adventure around the world as she searches for stories about living with diabetes. The program, sponsored by Novo Nordisk, enlightens viewers and offers physicians a chance to earn one AMA-approved CME credit. | | | GSK Told to Update Avandia Warnings
| | Faced with contradictory data about the safety of the diabetes treatment, FDA asks for a black-box warning and additional trials. But how much damage will the black box do? | | | Lilly's New Blood Thinner No Blockbuster
| | Safety Risks, Generic Threat Scale Down Big Hopes | | | Stormy Forecast for Pharma in 2008
| | Bright Spots Are Emerging Markets, Specialty Drugs, Says IMS Health | | | MORE ARTICLES
|
| |
| ASCO Roundup: Winners, Losers, and Also Rans
| | Due to pharma's voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week?s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida. | | | How Evidence Based Medicine is Impacting Global Clinical and Reimbursement Practices
| | Evidence-based medicine is fast becoming one of the key concepts in clinical and reimbursement practices in the developed world | | | Pfizer Pulls Two Late-stage Drugs from Development
| | A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them. | | | Transforming Clinicians into Industry Leaders
| | Could physician behavior have a positive impact on Drug Development? | | | Vaccines for All
| | The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. | | | Latest Flu Season Sets Tamiflu Back but Doesn't Knock It Down
| | The Tamiflu-resistant flu strain means increased sales for GSK's Relenza, but doesn't mean the end for the number-one antiviral. | | | Pfizer Sheds More Staff
| | Sales reps aren't the only ones heading for the unemployment line - Pfizer is eliminating researcher positions as fewer drugs are making it to development. But could streamlining the crux of drug R&D cause more harm than good? | | | Insuring Global Clinical Trials
| | As global regulators set up rules for liability insurance for clinical trials, the playing field has grown complex for sponsors. This article reviews the key issues and offers a look at how European, Asian, and Latin American countries handle clinical trial insurance. | | | Merck Submits Request to Market Gardasil to Men
| | Merck isn't bragging about the positive data it received regarding the use of its landmark HPV vaccine in men. But the pharma giant also isn't wasting time submitting the info to FDA. Pharm Exec talked to the lead investigator behind the trials to find out why this could be another milestone for Merck. | | | MORE ARTICLES
|
|
|
| Managing the Crisis of Marginalization
| | The key to managing the pharma sales force is to know when the customer wants good customer service, and when the customer needs good self-service. | | | Rx Scripts Spike in Wake of Swine Flu
| | New prescriptions for antiviral treatments get huge boost due to H1N1 epidemic. Numbers exceed those seen during this year's influenza season, and the numbers are climbing. | | | Higher Learning for Pharma Sales Reps
| | American Society of Hypertension to launch new education program that grants sales reps hypertension accreditation after rigorous training. | | | US Pharma Market To Decline in 2009
| | IMS has revised its 2009, forecast and the outlook isn't pretty for the United States, which looks to drop 1 to 2 percent in the coming year. | | | Goodbye, Willy Loman
| | The days of pharma sales reps going office-to-office with samples and brochures are done. These days, they need to turn their attention to payers, pharmacists, and consumers | | | Make a Match
| | Big Pharma is finally making a commitment to partner-based outsourcing. | | | Drug Sales See Minimal Climb in 2008
| | Farewell to double-digit growth. Between patent expirations and a sagging economy, sales of prescription drugs grew only 1.3 percent last year. | | | The New Sales Force
| | The arms race is over, and it's time to reinvent pharma sales. Here's what forward-looking companies are experimenting with—and how it's working | | | Physicians Continue to Limit Face Time with Reps
| | SK&A released grim news last week - nearly two-thirds of sales reps are either banned or forced to make an appointment before they can set foot in a doctor?s office. | | | MORE ARTICLES
|
| |
| Oscient Pharmaceuticals Lays Off 180 Reps
| | Oscient trims 180 sales, marketing, and corporate jobs in the wake of patent expirations, generic competition. | | | Emerging Leaders 2009: The Faces of Innovation
| | Our second annual Emerging Leadership Awards cast the spotlight on 27 young rising stars most notable for their dedication and contribution to the pharma industry. Here's a closer look at why. | | | Stealth Pharmas
| | The third annual audit reveals how pharma's "other half" performs. | | | Pay For Play
| | The P4P movement is here. Pharma marketers, it's time to take note. | | | Amylin Drops 200 Sales Reps
| | As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians.
| | | Bio Companies Low on Venture Capital Cash
| | As the economy continues to retract, fewer biotech companies are finding the funding they need to survive, driving more firms to sell or close shop. | | | Reading the "Risk Radar"
| | Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization. | | | Cancer Quagmire
| | Clear dialogue between manufacturers and payers will be essential to the process of transforming oral oncologic's dynamics. | | | The Shakeout
| | When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. | | | MORE ARTICLES
|
| |
| Calculating Risk
| | A risk-based approach to records and information management can be an integral part of the effort to reduce costs stemming from litigation. | | | Bank on IT
| | Tough economic tmes call for a bold approach to evolving information technology solutions. | | | Search for: Meaning
| | Here's how to search for meaning through unstructured data. | | | Ortho-McNeil Talks ADHD On Facebook
| | The Johnson & Johnson subsidiary launched an unbranded support group page on social networking site Facebook giving moms of kids with ADHD a place to learn, but not a place to converse. | | | J&J Goes From Boob Tube to YouTube
| | Johnson & Johnson launched its healthcare video channel on Google?s YouTube, signaling pharma?s further entrenchment into the online community | | | Genzyme Launches Digital Assault on Counterfeiters
| | Rather than wait to see which ePedigree legislation becomes law, biotech firm Genzyme has taken the initiative and implemented an electronic track-and-trace program to clamp down on fake meds. | | | Researchers to Share Ideas in Virtual Park
| | The Hershey Center for Applied Research is bringing social networking to researchers and academics with a new platform that could become a Facebook for the life science community. Does the site, dubbed KnowledgeMesh, have what it takes cut through the Web 2.0 clutter? Pharm Exec takes a closer look. | | | Sermo Joins With Med Mags
| | Still hoping the journal article on your drug's adverse reactions will go unnoticed? Think again. A new partnership between medical journals and physician social networking site Sermo just made chatting about drugs a lot easier. | | | Want to Be in a Health Plan? Think Like One
| | Pharmacoactuarial analysis helps drug companies communicate value to health plans | | | MORE ARTICLES
|
|
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
If you're searching for a new business location, attend the Business Facilities LiveXchange event and learn from location experts, meet with economic developers, and network with peers, all at no cost to you!